Cogent Biosciences UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you, everyone, for joining us in our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS, and very pleased to have Cogent Biosciences here with us. Up here on the stage is Andrew Robbins, the President and CEO of Cogent. Thank you very much for being here. It's a pleasure to see you.
Well, thanks for inviting us. We're happy to be here. It looks like the rain's stopping, so it's nice to be in London.
Perfect. Thanks for having us.
Perfect. Well, it is exciting times for Cogent, because Cogent is on the brink of two, or three actually, potential FDA approvals, and two of them coming potentially in the next couple of months. If we could just maybe start from a high-level perspective, can you talk about where Cogent is with your drug, and specifically where you are in the regulatory filings for which indications? Then maybe we can go into some of each of those.
Sure. Well, happy to do that. Very briefly, for those that aren't familiar, Cogent is a company that's focused on creating small molecule kinase inhibitors for patients with rare genetically driven diseases. Our lead asset is a drug known as bezuclastinib, which is a selective and potent KIT mutant inhibitor that's under development for three distinct patient populations. Two forms of a disease called systemic mastocytosis, both the advanced form and the non-advanced form, as well as imatinib-resistant gastrointestinal stromal tumor patients. For each of those indications, we completed a pivotal study. Interestingly, all three of those pivotal studies had their positive results readout in 2025. 2026 really was always meant to be a year of regulatory submissions and working with the FDA specifically to try to bring this medicine to these three distinct patient populations.
To Mike's specific question, we have formal PDUFA dates announced, and they remain in place for all three, with a November 30th, which is literally days away for our first, hopefully, approval in second-line GIST or imatinib-resistant GIST patients. Then on December 30th, a PDUFA date for the non-advanced systemic mastocytosis indication, which was from a trial called the SUMMIT trial. Then finally, for the advanced form of mastocytosis, which is June 29th of 2027, and that is based on the positive results from what's known as the APEX study. I'm sure we can talk a little bit about each of those.
Fantastic. Well, you have three filings going on at the FDA, so you're keeping the FDA busy. On November 30th, there's a PDUFA date. Let's kind of go through these chronologically. I think these are all huge opportunities. This is multi-billion. We'll talk about these opportunities each, but first we got to get approvals. In second-line GIST, which could be a couple billion dollars, unmet need, very strong phase III results. You have an FDA approval. Can you just talk about what your expectation is for approval? Do we expect a very clean label? Would there be any black box on this? Because investors say your drug is on top of SUTENT versus SUTENT alone.
Yeah. Fantastic data, but SUTENT has a black box.
How does that work? Does your drug get a black box on that, or it doesn't get a black box?
Right. We're obviously very aware of this narrative. What I can tell you is a few things. Number 1, we, in our opinion, have very carefully characterized the behavior of bezuclastinib. Bezuclastinib does really one thing exceptionally well, and that targets and kills cells that have KIT mutations in them. From a tolerability perspective, across all of our studies in a patient database, which is now well above 1,000 people who have taken our drug, it's a very consistent safety profile. It really does three things. At a low level, sometimes patients report that they have salty taste changes. Patients sometimes demonstrate white hair growth, which is an on-target effect of hitting KIT.
The one that people talk about the most, as a tyrosine kinase inhibitor, which is a pretty common adverse event for tyrosine kinase inhibitors, we have demonstrated that the drug can cause fluctuations in transaminases. What's important, though, is across all these studies, at all the various doses, we don't have a signature of the drug causing clinical sequelae as a result of the transaminase fluctuation. In almost all patients, without any dose modifications, we can give the bezuclastinib chronically to people.
In a smaller number of patients with a dose reduction, those patients can resolve to baseline levels and take the drug chronically. Only in very, very rare cases have we had to withhold the drug from someone or discontinue the drug. In every one of those cases, the patient's transaminase levels went back to baseline with no clinical sequelae.
If a patient has second-line GIST cancer, I don't think people are concerned about white hair or salty taste.
I agree with that. Given ALT is a common concern, and certainly not a concern for cancer, I don't think this is a concern.
The idea was that I would love to offer you the opportunity, and certainly I've been saying, but I'd like to understand why would a black box matter in GIST? As I appreciate that if there was one, wouldn't it just be cut and paste from the same SUTENT label?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
